Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
187 hedge funds and large institutions have $3.83B invested in Apellis Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 73 increasing their positions, 53 reducing their positions, and 36 closing their positions.
87% more call options, than puts
Call options by funds: $44.3M | Put options by funds: $23.7M
67% more capital invested
Capital invested by funds: $2.29B → $3.83B (+$1.54B)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
38% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 53
22% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 36
4.46% more ownership
Funds ownership: 79.91% → 84.37% (+4.5%)
3% more funds holding
Funds holding: 181 → 187 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$159M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$140M |
| 3 |
RI
RTW Investments
New York
|
+$78.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$45.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$35.6M |
| 2 |
Goldman Sachs
New York
|
-$20.7M |
| 3 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$20.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$20.1M |
| 5 |
Two Sigma Advisers
New York
|
-$18.1M |
APLS Hedge Fund Activity: Q4 2021 in Review
187 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2021, worth a combined $3.83B — up 67% from $2.29B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new APLS positions and 36 closed out — a net gain of 8 holders — while 73 added to existing stakes and 53 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $159M. The largest seller was Citadel Advisors, cutting an estimated $35.6M.
- 187 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2021, up from 181 in Q3 2021.
- Funds reported $3.83B of Apellis Pharmaceuticals stock for Q4 2021, up 67% quarter-over-quarter.
- 44 funds opened new Apellis Pharmaceuticals positions in Q4 2021 and 36 closed out, a net change of +8 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2021 was EcoR1 Capital, an estimated $159M added.
- The largest Apellis Pharmaceuticals seller in Q4 2021 was Citadel Advisors, an estimated $35.6M sold.
Based on aggregated 13F filings for Q4 2021.